title: Protection of piglets by a Haemophilus parasuis ghost vaccine against homologous challenge.
abstract: Commercial bacterins for Glässer's disease are widely used for the prevention of this disease caused by Haemophilus parasuis; however, the protective efficacy varies depending on the strain and serovar. Bacterial ghosts (BGs) are empty bacterial envelopes that, unlike classic bacterins, suffer no denaturing steps during their production. These properties may lead to superior protection. In this study, a BG vaccine generated from the Haemophilus parasuis serovar 5 reference strain Nagasaki was prepared and used to inoculate piglets. The efficacy of the BG vaccine was evaluated by clinical, bacteriological, serological, and postmortem examinations. Inactivated bacterin (IB) and a placebo control (PC) were compared with the BG vaccine in this study. The results showed that the piglets inoculated with the BG vaccine developed higher antibody activity and higher gamma interferon and interleukin 4 levels than those vaccinated with IB or those in the PC group after primary and secondary exposure to the antigens and challenge. CD4(+) T lymphocyte levels were observed to increase following secondary immunization more in the BG-vaccinated group than in the IB (P < 0.05) and PC (P < 0.05) groups. CD8(+) T lymphocyte levels increased dramatically in all three groups after challenge, and the differences between groups were all significant (P < 0.05). There were fewer tissue lesions and lower bacterial loads in the tissue homogenates in the BG group after challenge. The results suggest that higher CD4(+) T lymphocyte levels and both CD4(+) major histocompatibility complex class II-restricted Th1-type and Th2-type immune responses in the BG group are relevant for protection.
authors.affiliation: Division of Bacterial Diseases, State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute of Chinese Academy of Agricultural Sciences, Harbin, People's Republic of China.
authors.forename: Mingming
authors.initials: M
authors.lastname: Hu
authors.forename: Yanhe
authors.initials: Y
authors.lastname: Zhang
authors.forename: Fang
authors.initials: F
authors.lastname: Xie
authors.forename: Gang
authors.initials: G
authors.lastname: Li
authors.forename: Jianjun
authors.initials: J
authors.lastname: Li
authors.forename: Wei
authors.initials: W
authors.lastname: Si
authors.forename: Siguo
authors.initials: S
authors.lastname: Liu
authors.forename: Shouping
authors.initials: S
authors.lastname: Hu
authors.forename: Zhuo
authors.initials: Z
authors.lastname: Zhang
authors.forename: Nan
authors.initials: N
authors.lastname: Shen
authors.forename: Chunlai
authors.initials: C
authors.lastname: Wang
mesh_terms: D000825:Animal Structures / Q000473:pathology; D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood; D058491:Bacterial Load; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000276:immunology*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D049109:Cell Proliferation; D006192:Haemophilus Infections / Q000276:immunology / Q000473:pathology / Q000517:prevention & control / Q000662:veterinary*; D044137:Haemophilus parasuis / Q000276:immunology*; D007371:Interferon-gamma / Q000378:metabolism; D015847:Interleukin-4 / Q000378:metabolism; D013552:Swine; D013553:Swine Diseases / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000276:immunology
chemical_list: D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines; D015164:Vaccines, Inactivated; D015847:Interleukin-4; D007371:Interferon-gamma
references.citation: Adv Exp Med Biol. 2009;655:159-70
references.pmid: 20047041
references.citation: J Biotechnol. 1996 Jan 26;44(1-3):161-70
references.pmid: 8717400
references.citation: J Biotechnol. 2000 Sep 29;83(1-2):161-72
references.pmid: 11000472
references.citation: Vaccine. 2009 Aug 20;27(38):5271-7
references.pmid: 19576561
references.citation: Res Vet Sci. 2009 Apr;86(2):230-4
references.pmid: 18783806
references.citation: J Immunol. 2004 Jun 1;172(11):6858-65
references.pmid: 15153504
references.citation: Adv Drug Deliv Rev. 2005 Jun 17;57(9):1381-91
references.pmid: 15878634
references.citation: Expert Rev Vaccines. 2004 Dec;3(6):681-91
references.pmid: 15606353
references.citation: Expert Rev Vaccines. 2003 Feb;2(1):45-51
references.pmid: 12901596
references.citation: J Biotechnol. 2000 Sep 29;83(1-2):57-66
references.pmid: 11000461
references.citation: Expert Rev Vaccines. 2007 Apr;6(2):241-53
references.pmid: 17408373
references.citation: J Comp Pathol. 2009 Feb-Apr;140(2-3):169-76
references.pmid: 19135210
references.citation: Immunobiology. 2011 May;216(5):558-65
references.pmid: 21247655
references.citation: Vet Microbiol. 2004 Mar 26;99(1):1-12
references.pmid: 15019107
references.citation: Res Vet Sci. 2012 Aug;93(1):51-6
references.pmid: 21596404
references.citation: Arch Microbiol. 1992;157(4):381-8
references.pmid: 1534215
references.citation: Vaccine. 2000 Jul 1;18(26):2945-55
references.pmid: 10825595
references.citation: FEMS Microbiol Lett. 1999 Oct 1;179(1):153-60
references.pmid: 10481100
references.citation: Vet Immunol Immunopathol. 2002 Jul;86(3-4):221-8
references.pmid: 12007888
references.citation: J Bacteriol. 1990 Jul;172(7):4109-14
references.pmid: 2141836
references.citation: J Biotechnol. 1999 Aug 20;73(2-3):261-73
references.pmid: 10486935